Genmab — December 2012
-
In pts with relapsed or refractory MM treated with daratumumab, a marked reduction in paraprotein and bone marrow plasma cells was observed in the higher dose cohorts. This has not previously been demonstrated with a single-agent monoclonal antibody in MM. No unexpected buildup of daratumumab was seen and in pts treated with 4mg/kg and upwards the observed plasma concentrations were close to those predicted
-
Var det ikke også torben plesner på arzerra
-
De har i gennemsnit været behandlet 6,3 gange før så det er imponerende
-
Markedet er også større, men vi er jo laangt fra markedet
-
Men det bliver spændende om han i guidance vil løfte sløret for milestones sammensætningen
-
Mr. Market har jo ikke lagt meget fedt flæsk ind i kursforventningerne, så når det her begynder at blive foldet ud klinisk, så kan det bære rimeligt meget løft i kursen
-
Giver det noget imorgen tror I?
-
aka tror ikke så meget det er de nye data
-
nok mere at de præsenterer de her, sagt det lige ud, fantastiske daratumumab data foran de største læger og analytikere i verden
-
Svært at sige hvad de sidste data giver - tror mest af alt den handler om, hvor meget omtale og opsigt præsentationen har givet. Det ser vi muligvis ikke på førstedagen, men nok snarere over de kommende dage, når der kommer lidt referater diverse steder fra !
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind